Atara Biotherapeutics (ATRA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ATRA Atara Biotherapeutics

Watchlist

7.895
+0.225+2.93%

Trading Aug 9 10:16 ET

38.72MMarket Cap-148P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
BusinesswireAug 7 16:01 ET
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Cuts Target Price to $13
Moomoo NewsJul 18 07:31 ET · Ratings
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
TipRanksJul 18 06:46 ET
Atara Lead Asset Tab-cel Undergoes FDA Priority Review
Seeking AlphaJul 17 15:39 ET
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs
Dow JonesJul 17 12:08 ET
Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs
Dow JonesJul 17 12:08 ET

Comments

Trytosaveabit

Jul 17 08:09

Update! Make a note!

$Atara Biotherapeutics (ATRA.US)$ Reuters· PDUFA for BLA is January 20th
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA

Trytosaveabit

Jun 17 07:08

Update

$Atara Biotherapeutics (ATRA.US)$ Atara Biotherapeutics To Conduct 1-for-25 Reverse Stock Split, Effective Jun. 20

Trytosaveabit

May 29 15:12

Update

$Atara Biotherapeutics (ATRA.US)$ Reuters· 7 mins ago
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases

Jaguar8

May 29 15:02

NEWS

$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...

Jaguar8

May 20 08:36

$Atara Biotherapeutics (ATRA.US)$
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

ATRA Atara Biotherapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target